CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group has received approval from the U.S. FDA to conduct clinical trials for its new drug, SYH2051, a selective ATM inhibitor targeting advanced solid tumors. This approval, alongside prior approval in China, marks a significant step in the company’s oncology research, potentially enhancing its market position and offering promising treatment options for cancer patients.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on the development and production of innovative drugs, with a particular emphasis on oncology treatments.
YTD Price Performance: 3.56%
Average Trading Volume: 4,371
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.15B
See more data about 1093 stock on TipRanks’ Stock Analysis page.